

























AppEndix A: AHN IRB NO PURVIEW LETTER	31
APPENDIX B: BLANK PRE- AND POST-INTERVENTION SURVEYS	32
Appendix C: stata output from power analysis	34
bibliography	37
List of tables
 TOC \h \z \c "Table" Table 1. Results of Pre- and Post-Epic Implementation Surveys	21
Table 2. Estimated Sample Sizes Required for Statistical Significance of Survey Questions	22
preface








In my administrative residency with Allegheny Health Network’s (AHN) Research Institute, I was afforded the opportunity to witness the deployment of two electronic platforms for patient management: Epic, the electronic health record (EHR) implemented across the Allegheny Health Network and Clinical Conductor, a clinical trial management system (CTMS) used to manage patient recruitment and clinical trials financials. I was trained on the basic capabilities of Epic over a two day period for a total of sixteen hours. As I progressed through my residency I noticed that there were several opportunities to optimize the use of Epic for clinical research purposes.
Epic training provided a general overview of the EHR.  It did not give a more specific demonstration and/or use case of the system’s capabilities, E.g. using the system to register and schedule patients in the Esophageal and Lung Institute, reconciling patient billing questions with invoices “dropped” from the “back office,” rescheduling patients because they presented to their specialist’s office without a prior authorization for diagnostic imaging. 
The problem presented to me during my residency was that electronic platforms currently implemented across Allegheny Health Network (AHN) are not being optimized for clinical research subject identification and retention
The following are objectives of my essay: 1) gauge the effectiveness of Epic as a screening tool before and after implementation of an “out of the box” clinical trials feasibility tool - SlicerDicer; 2) assess areas to improve subject/volunteer identification for recruitment within the EHR; and 3) analyze clinical research coordinator attitudes about Epic and CTMS as a whole. Assessment of these objectives will help to determine whether the interventions implemented by AHN increased the effectiveness of Epic and where improvement is needed. CRC attitudes are important because these individuals are utilizing Epic on a daily basis for clinical trial operations and their feedback must be taken into consideration. 
The AHN Research Institute is at the forefront of research on a local, regional, and national level. The institute offers new drug therapies, revolutionizes surgical procedures, and offers innovative devices and wearable technology that reduces the impact of chronic disease. Through partnerships with industry, government, academia, and health systems across the Pittsburgh region, best practices in medicine are developed. By creating new methodologies in treating disease, the AHN Research Institute improves the health of its patient base while advancing the science of medicine. 
Clinical trials are the foundation of sound decision making in health care. Within the AHN Research Institute, clinical trials activities are operationalized in three sub-disciplines. The first sub-discipline, laboratory science, is when principal investigators and scientists work in hospital laboratories to discover new molecules and methods for treating disease. The second sub-discipline, translational science, is when new therapies, proven to be safe in the laboratory, are offered to a small sample of patients to determine dosing levels and first-in-human safety. The third sub-discipline, clinical research, is when the intervention, proven to be safe in a small group of patients, is offered as part of a larger and controlled, nation-wide study. Allegheny Health Network offers hundreds of these types of clinical trials. Once the safety and effectiveness of a medication, treatment or therapy is proven, it becomes the new standard of care and best-practice for treating a particular disease. All of these steps are necessary in the advancement of science and precision medicine, helping to improve patient care and promote better patient outcomes. 
2.0 	Literature review
Before an in-depth overview of electronic health records and their importance within clinical research, it is important to differentiate between basic science, translational, and clinical research. Basic science research – often called fundamental or bench research – provides the foundation of knowledge for the applied science that follows. This type of research encompasses familiar scientific disciplines such as biochemistry, microbiology, physiology, and pharmacology, and their interplay, and involves laboratory studies with cell cultures, animal studies or physiological experiments. Basic science also increasingly extends to behavioral and social sciences as well, which have no less profound relevance for medicine and health.1 For many, translational research refers to the “bench-to-bedside” enterprise of harnessing knowledge from basic science to produce new drugs, devices, and treatment options for patients. For this area of research – the interface between basic science and clinical medicine – the end point is the production of a promising new treatment that can be used clinically or commercialized. Meanwhile, for others – especially health services researchers and public health investigators whose studies focus on health care and health as the primary outcome – translational research refers to translating research into practice; ie, ensuring that new treatments and research knowledge actually reach the patients or populations for whom they are intended and are implemented correctly. The production of a new drug, an end point for “bench-to-bedside” translational research, is only the starting point for this second area of research.2 This leads into clinical research, which is research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Clinical research includes mechanisms of human disease, therapeutic interventions, clinical trials, development of new technologies, epidemiologic and behavioral studies, and outcomes and health services research.3 Now that clear distinctions have been made between basic science, translational research, and clinical research, the focus can be shifted to EHRs and how they have become essential within clinical research. 
Electronic health records (EHRs) are becoming increasingly important within clinical research. Clinical research requires collaboration between clinicians and researchers, but often the collaborations are poorly supported. The Institute of Medicine has called for a ‘learning healthcare system’ to accelerate cost-effective generation of new evidence directly from and applicable to patient care processes. The model envisions conducting clinical research as a result of patient care.4 The increasing adoption of EHRs offers the opportunity to permit rich data collection and longitudinal analysis of patients and to increase coordination between patient care and patient-oriented activities, while reducing the burden placed on physicians, patients, and healthcare delivery.4  In 2014, seventy-six percent of U.S. non-Federal acute care hospitals, had adopted at least a basic EHR system, which represents an increase of twenty-seven percent from 2013 and an eight-fold increase since 2008. Nearly all of those hospitals, ninety-seven percent, possessed a certified EHR technology in 2014, increasing by thirty-five percent since 2011. Non-federal acute care hospitals include acute care general medical and surgical, general children’s, and cancer hospitals owned by private/not-for-profit, investor-owned/for-profit, or state/local government and located within the fifty states and District of Columbia. Basic EHR adoption requires that each function be implemented in at least one unit in the hospital. Possession of certified EHR is considered to be either the physical possession of the medium on which a certified EHR system resides or a legally enforceable right by a health care provider to access and use, at its discretion, the capabilities of a certified EHR system.5 EHRs can be used to automate prescreening and can significantly improve recruitment efficiency and costs. However, for all of the improvements EHRs can provide for research, barriers still exist in perfecting the optimization. 
Several barriers are present that can be improved in achieving optimization of EHRs for research. Inaccurate diagnosis codes and problem list can cause errors in electronic prescreening of patients. The notion of data analytics and informatics intervention in clinical documentation, while unorthodox, is a needed intervention post-EHR implementation. Institutional privacy rules can limit use of EHRs to prescreen patients for research and access can be granted to medical records to collaborating researchers, called preparatory to research. Given the sorted history of research practice, patient privacy protections have been outlined in the Federal Register and strictly enforced by regulatory bodies – both internally through local internal review boards (IRBs), and externally through governmental agencies (FDA, HRSA, etc.) and central IRBs.  While human subjects protections take precedence over the practice of clinical research at-large, it is critical that a balance be stuck between regulatory oversight, and the societal benefits achieved through clinical research.4 Current research practices require informed consent and EHRs have the potential to enhance the process. 
Another issue that is highly controversial with EHRs and research is that of patient privacy and consent. Privacy can be defined as the ability to control the collection, use, and disclosure of one’s personal information.6 Traditionally, policies to protect privacy in research have relied upon anonymization of the data, and in the case of research using identifiable information, seeking the prior consent or authorization of the individual.6 However, there is a large gap between the ideal of informed consent and the practice of obtaining consent or authorization in practice.7 Consent forms are often too lengthy or opaque for people to understand, people are unlikely to read the forms in any case, and people may not have (or feel they have a reasonable alternative to consenting.8
The ‘consent model’ and the ‘trust model’ are two possible approaches to address some of the challenges for a research network based on federated EHRs. A federated EHR model consists of a collection of clinical data repositories which are located remotely. In this model, patient data is not stored in a centralized, accessible location and continues to be stored locally.9 It is debatable whether explicit consent is required for reuse of key-coded EHR data for research and statistical purposes. In some countries, special legislation may require primary EHR data to be submitted for public health purposes to national or regional registries without the need for consent of the data subject.9 The ‘trust model’ approach reduces the information content of the data so that individuals can no longer be identified. However, the uncertainties of the legal position of ‘nearly anonymized’ data make it difficult for researchers to know when they are being compliant with the law while using EHRs for research.9
The issues of biospecimens, consenting and genetics in clinical research were clearly illustrated by the case of Moore v. Regents of the University of California. John Moore, a patient who underwent treatment for leukemia at UCLA Medical Center filed an action against his physician Dr. Golde and others, because they used cells extracted from him in lucrative medical research which eventually yielded a patented cell line without his permission. Moore alleged thirteen claims, including a breach of physician’s duty to disclose competing interests that may affect medical judgment, lack of informed consent, and conversion. The court held that a physician who is seeking a patient's consent for a medical procedure must, in order to satisfy his fiduciary duty and to obtain the patient's informed consent, disclose personal interests unrelated to the patient's health that may affect his medical judgment. The court ruled Moore had no cause of action for conversion because once the cells were extracted from Moore’s body; he no longer had any claims of ownership over them.10
In 2013, several changes were made to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule to streamline informed consent. The changes to the HIPAA Privacy Rule include permission to obtain a single authorization to use protected health information (PHI) in both “conditioned” research activities (such as clinical trials, in which individuals cannot receive a particular treatment unless they agree to the use of their PHI) and “unconditioned” research activities (such as optional tissue and data banking); permission to simultaneously obtain authorization to use PHI in both current research and future research, provided the future use of PHI is described with enough specificity that a reasonable person would expect that it would be used for that purpose; and clarification that, for the purposes of HIPAA, genetic information is “health” information, though, not on its own, identifiable.11 In theory, the new HIPAA rules allow researchers to obtain, in a single authorization document, permission to use a participant’s data for a clinical trial, permission to bank the participant’s tissue/data for future research, and permission to use the participant’s data for future research, provided that the document includes a description of the research that has a degree of specificity that is acceptable to the institutional review board (IRB) and gives the participants a reasonable idea about the nature of the research.11
Preparatory research is one of the areas where HIPAA has impacted subject recruitment and retention. The purpose of preparatory research is to review PHI to prepare a research protocol or to facilitate subject recruitment by identifying prospective research subjects for purposes of seeking their authorization to use or disclose PHI for a research study.12 Prior to performing preparatory research, the researcher completes a Preparatory to Research form and submits it to their IRB or Privacy Board. On the form, the researcher outlines the purpose of the review, what specific PHI will be used and/or disclosed, why the PHI is necessary for the research, where the information is located, and how and by whom the information will be accessed. The researcher agrees not to remove any PHI from the covered entity and to follow the minimum necessary standard.12 A covered entity may require the individual who accesses medical records for preparatory research or recruitment to be an employee of the covered entity.12
Pre-screening of potential subjects is another area where HIPAA has reached. A researcher can pre-screen potential subjects over the telephone with the use of a HIPAA Waiver of Authorization. The researcher needs to demonstrate that the research could not practicably be done without a waiver, the research could not practicably be done without PHI, the subject’s rights and welfare will not be adversely affected, there is a reasonable risk to benefit ratio, the use or disclosure plan involves no more than minimal risk to privacy, and a plan to protect identifiers and destroy identifiers at the earliest opportunity.12
Due to preparatory to research requirements, screening in academic medical centers is especially difficult. It is quite possible that a primary investigator would not be the patient’s attending of record, and that the patient would be seeing multiple providers at one point in time. Having multiple providers increases the probability of a patient meeting an exclusion criteria and thus, harms subject recruitment and retention. To address these issues, case-based reasoning using EHRs can also be used to identify eligible patients for clinical trials.
EHRs have been proven to be useful for efficiently identifying eligible patients for clinical trials to reduce potential delays due to recruitment difficulties. Due to differences in semantic representations for key eligibility concepts between EHRs and eligibility criteria, the “case-based reasoning” (CBR) paradigm is useful. The purpose of CBR is to use previous knowledge and experiences to solve a new problem. In this case, the “new problem” refers to discovering patients eligible for a trial, whereas the “previous knowledge” can be seen as the set of enrolled clinical trial patients.13 Case-based reasoning represents a novel combinatory reuse of clinical and research data and research data from clinical trial management systems, specifically the information about trial participants, to improve clinical trial recruitment and screening. In particular, the feasibility of using EHR data of clinical trial participants to recommend potentially eligible patients to a trial without processing its free-text eligibility criteria or requiring identifying controls for designing classifiers has been demonstrated. The CBR approach can be applied in several capacities. It can be used as a self-standing tool, which constantly monitors a clinical data warehouse and alerts investigators when a new potentially eligible patient is identified.14 Additionally, an investigator can use CBR to rake all the patients in a data warehouse. And finally, depending on the data types included in the EHR patient representation, the framework may allow for a high-degree of interoperability.11 While the CBR approach can be considered a successful one, many barriers still remain when utilizing automated clinical trial screening. 
The barriers to efficient use of automated eligibility screening systems are three-fold. First, although automated eligibility screening systems should ideally be evaluated on real-world data, the goal is hindered by the lack of access to production EHRs. Second, not all automated eligibility screening algorithms proposed in the literature improve performance. Third, few studies explicitly report trial screening efficiency with and without automated eligibility screening.15 Another issue is that inclusion/exclusion criteria are becoming increasingly stringent and specific, and the result is the recruitment of exceedingly homogenous subject pools. The homogenous subject pools are important for efficacy studies, but they are atypical for real practice settings and therein lies the problem.16 Automated screening will keep subject pools homogenous as long as the screening system is able to analyze all subject recruitment criteria. Another issue with subject recruitment is the amount of time needed to identify eligible patients. 
EHRs are a much more efficient way to identify patients for clinical trials. Hand-searching paper medical records of varying quality and legibility is an inefficient use of time. Organization of paper medical records can vary between practices or even between providers within the same practice. Often, information in the paper medical records is not accurate with conflicting information such as contact information, age, and chronic medical problems.17 Because EHRs have become more commonplace in primary care offices, more investigators have been able to take advantage of databases to identify possible participants for clinical studies. The content within an EHR is crucial to determining study eligibility criteria. Studies that have more complicated eligibility criteria might have more difficulties finding potentially eligible patients. Also, EHRs may not routinely capture race and ethnicity in all patients, which can be a problem, considering that disparities exist in clinical trial participation among medically underserved populations.18
To address disparities in clinical trial participation, patient navigation can be utilized. Simply, patient navigation is a strategy for increasing patients’ access to care by helping them overcome barriers in their communities, and within the health system.18 Navigators provide a bridge between the patient and the healthcare system. Specifically, in cancer trials, navigation has been a success. Studies reported clinical trial enrollment that ranged 61% to 86% among study eligible minority patients, demonstrating patients’ willingness to participate in clinical trials.19 However, there are challenges that still exist. There is a low number of available clinical trials for minority patients, who may be deemed ineligible due to presentation at higher cancer stages and increased co-morbidities.20 Exclusion of potentially clinical trial eligible patients due to co-morbidities has also been documented among African-American cancer patients and is a persistent challenge for minority patients accrual into clinical trials.18 Along with the previous methods of subject recruitment for clinical trials, data can also be used as a recruitment tool. 
Eligibility criteria not only specify the population for a study; they drive recruitment, selecting subjects for observational studies and generalizability of results. Eligibility criteria are usually expressed as descriptive text rather than combinations of discrete clinical data elements, but formally structured representation of eligibility criteria is increasingly useful in the era of EHRs, to facilitate various research functions including evaluating feasibility, cohort identification, and trial recruitment.21 If eligibility criteria are broken down into criteria elemental statements (CES), they can potentially be addressable in a typical integrated EHR. EHR data, on its own can be useful for identifying patient cohorts for trials, but EHR data alone is often insufficient to identify an individual patient as a suitable trial subject.21 Use of structured data elements can frequently expedite the screening process for enrolling patients and in a small proportion of trials be entirely sufficient.21 Integrated data capture can increase efficiency by streamlining data collection. 
Research systems, often known as data capture systems or clinical trials management systems (CTMS), work alongside EHRs to track the additional clinical and financial information required by law. To ensure appropriate reimbursement for the services provided to a patient in a clinical trial, research sites must develop a budget for each trial and must conduct a Medicare Coverage Analysis (MCA). This identifies the services for which Medicare will pay under the Medicare Clinical Trial Policy. Non-compliant billing is subject to severe penalties, as well as civil and criminal actions. The first step is to determine whether the trial qualifies for coverage.22
To qualify, a trial should meet the following criteria. The purpose of the trial must be to evaluate an item or service that falls within a Medicare benefit category. The trial must have a therapeutic intent, in that it could potentially improve the participants’ health outcomes. The trial must also enroll patients with a diagnosed disease rather than healthy volunteers. Some trials are deemed to have the desirable characteristics and automatically qualify. Trials that would automatically quality are trials funded by a federal agency, such as the National Institutes of Health or the Centers for Diseases Control and Prevention, trials supported by a center or cooperative group that is funded by a federal agency, trials conducted under an investigational new drug application reviewed by the Food and Drug Administration, and drug trials that are IND-exempt.22 
Integrated data capture can provide many benefits for EHR systems. Integrated data capture streamlines the research data capture process by allowing a user to bypass the typical steps required in completing electronic case report forms. Integrated data capture also reduces the risk of a transcription error because data are entered directly into the electronic case report form, as opposed to manually. The electronic case report form data contain details about the capture of the information in the EHR. These values are synchronized with the EHR, and the details of changes are recorded, providing a complete, clear sequence of events, thus providing support for audits and monitoring visits. Finally, while working in a study participant’s EHR record, a care provider can submit the data to the electronic case report form in real time. This capability prevents a time lag between EHR capture and transcription of data, allowing for participants’ data to be captured and finalized more quickly.23 Integrated data capture provides many benefits to users, but there is also room for improvement. This was done by adding additional data categories to the electronic case report form, limiting overrides of data, creating more flexibility for inputting data values, indicating when data collection mode is active, providing more specific information for audit purposes, condensing repeating data, and by grouping related data elements together.23
Another important element in data capture is remote monitoring. Monitoring is an FDA- mandated process whereby the integrity of the clinical trial process is validated. The validation process includes site visits to inspect personnel, facilities, equipment, processes, and source and regulatory documentation. Monitoring, specifically, is estimated to be about one-third of any prospective clinical trial operating budget. Remote monitoring allows pharmaceutical companies and contract research organizations (CROs) to remotely conduct monitoring activities that were previously conducted on-site. This includes delivering documents to a clinical research associate (CRA) via email, fax, or snail mail to satisfy monitors’ queries and conduct source document verification. Remote monitoring has been challenging to date because the industry lacks accessible infrastructure to allow HIPAA and 21 CFR Part 11 compliant access to patient records, regulatory documents, and trial master file content for monitoring. Perhaps, a remote monitoring system would be beneficial in the future to better assist CROs, pharmaceutical companies, and research centers.24 
Research as a field is extremely complex. Not only are there different methods of research, from basic science to translational and clinical research, but there are many regulations and laws that aim to protect the privacy and well-being of research subjects. With the advent of electronic health records, research has become inherently more complex and with the ease with which information can be accessed, this has put research and those who work in the field in a precarious position. Ultimately, though, the trends of medicine have dictated this path and those who chose research as a career will have to navigate the landscape with trepidation. 

3.0 	Interventions
AHN has implemented four innovative tools and has customized them to increase efficiencies within the Research Institute. Coordinators now have access to pend orders, labs, and scans and can also document visit notes and telephone encounters. A custom tool called the emergency department (ED) visit report was created. SlicerDicer allows providers to look at deidentified patient data and run database queries to identify those patient populations with clinical criteria for particular research studies. They can use the information to potentially develop targeted interventions for patients or to place them in relevant clinical trials post-consent. Clinical Conductor, a clinical trial management system (CTMS) has been used to manage patient recruitment and clinical trials financials. These interventions have a clear utility for the Research Institute and are why AHN is leading the way in clinical research. 
The ability of coordinators to pend orders, labs, and scans and the ability to document visit notes and telephone encounters is of great importance. It allows for continuity of care in that primary investigators are able to keep tabs on study patients at all times. Information is able to be disseminated much more efficiently and patient safety improves because those involved with the study are informed at all times. Other institutions allow coordinators read-only access and AHN is leading the way in this respect.
The ED visit report is an important intervention for several reasons. If patients on study present to the ED, it is essential that their primary investigators be informed so that it can be determined if the episode is related to the study drug. If that is the case, the patient must be unblended. This is also an efficient way to track adverse events of study participants. Prior to Epic’s implementation, there was not a standard process for addressing the concern. 
There are two phases to AHN’s rollout of SlicerDicer. Phase I, which ties into the pre-/post-intervention survey, is feasibility completion, and Phase II is screening while avoiding preparatory to research issues. 
The fourth intervention is Clinical Conductor, a CTMS used to manage patient recruitment and clinical trials financials. Clinical Conductor has many features that AHN utilizes to efficiently run its research operations. With Clinical Conductor, AHN can achieve the following financial objectives: set and track budgets and payments, ensure billing compliance for single and multi-arm studies, leverage unparalleled financial granularity, and easily set multiple budgets for the same study. Clinical Conductor also assists with patient recruitment. Study coordinators can sync and search the patient database for patients, track campaign effectiveness and increase return on investment (ROI), utilize CMTS web recruitment, and analyze the patient database to determine trial feasibility. AHN can also track trial visits and resources and check patients in and out for visits in real time, schedule patient visits within a required window, store patients in the CTMS database, and quickly pay patients with easy-to-use debit payment systems. 
Though all of these interventions have aimed to increase efficiencies within the Research Institute, barriers still exist within Epic. Not every individual is granted the same access to patient information within Epic. This keeps patient PHI from being spread to ill-equipped personnel, but it inhibits lines of communication between healthcare personnel. Epic also had a great amount of downtime and seemed to always be going through systemic updates. Training for use was also far too simplistic and did not give an accurate portrayal of day-to-day functionality. The barriers that exist show that Epic, though a strong EHR system, can still be improved. 
4.0 	Study Design and methods
The study design is a pre-/post-interventional quantitative survey to measure research study coordinator perceptions of the observed interventions aimed to optimize electronic screening and other clinical research capabilities. The pre-/post-interventional survey was sent to thirty-nine and thirty-one CRCs and administrative directors respectively. The surveys asked questions of the CRC experience with Epic regarding the following criteria: the ease of screening, the accuracy of applicable patients and how well they are identified, the individual CRC perception of time spent screening, the individual CRC perception of Epic, and effectiveness of adverse event reporting. Approval was gained from the Allegheny Health Network IRB stating that my study was a quality assurance/quality improvement initiative. This will assist in deciding whether to pursue different strategies for optimizing electronic screening or whether long-term solutions have been discovered. 
	The data was collected using survey questions answered on a 1 to 10 scale, 1 being the most negatively associated response choice, 5 being a fair response choice, and 10 being the most positively associated response choice. The method of analysis was mostly quantitative with average scores calculated for each pre- and post-survey question with sporadic qualitative responses utilized when appropriate to supplement quantitative responses. Limitations of the data are numerous. This project was specific to Allegheny Health Network and thus only included clinical research coordinators employed in the network. This made the sample size smaller and the findings less generalizable than if CRCs from other health systems were surveyed as well. In addition, participation in the pre-modification survey was less than expected, with nineteen to twenty-three out of the thirty-nine study coordinators and fifteen out of the thirty-one study coordinators tasked to complete the pre- and post-surveys submitting responses.
Key sources of information that will inform key objectives of the study are the qualitative responses by CRCs. This information will give direct insight into daily struggles with Epic and will provide valuable feedback for potential solutions for optimization. The quantitative scores will also be important because the closer the average scores are to 1 for a certain area, the more attention that area should be paid. If an area has a score closer to 10, the less attention that area should be paid. 
The findings of the pre-/post intervention survey are broken down by number of responses and average score. The number of responses varied because coordinators decided not to answer the question or simply were unaware of Epic’s capability to perform a function. The average score for each question was calculated by dividing the total score by the number of responses for each question. In order to see if I could extrapolate my findings to the entire population, I performed a power calculation. Given my sample size, I would need to have a large effect size that could account the effect of my test variable despite the random variation within my sample.  Findings are presented in table format on the following pages. 


5.0 	FINDINGS AND ANALYSIS 
Table 1. Results of Pre- and Post-Epic Implementation Surveys
Topic	Number of Responses	Average Score	Topic	Number of Responses	Average Score
Ease of Screening based on diagnosis only using Epic	23	4.26	Ease of Screening based on search criteria available in SlicerDicer	14	7.57
Ability of Epic to identify applicable patients accurately	22	4.95	Ability of Epic to identify applicable patients accurately	15	7.37
Perception of time spent on screening patients	23	6.80	Perception of time spent on screening patients	15	3.93
Perception of Epic as an EHR system as a whole	23	6.83	Perception of Epic as an EHR system as a whole	15	7.87






Table 2. Estimated Sample Sizes Required for Statistical Significance of Survey Questions
Topic	Required Sample Size (n)	Power (β)
Ease of Screening based on diagnosis only using Epic/SlicerDicer	5	0.02
Ability of Epic to identify applicable patients accurately	56	0.02
Perception of time spent on screening patients	8	0.02
Perception of Epic as an EHR system as a whole	29	0.02
Usefulness of Epic in generating adverse event reports	121	0.02
 
*α = 0.05	
	Based on the results of the pre-/post-intervention survey, key findings were discovered. Based on opinions of ease of screening, pre- and post-SlicerDicer, there was an improvement from 4.26 out of 10 to 7.57 out of 10. Coordinators believed that the search criteria available in SlicerDicer would be an asset towards optimizing screening. Coordinators believed that SlicerDicer would help them achieve a more accurate estimate of the target populations in study protocols and that familiarity with the tool will assist in navigation. Based on opinions of the ability of Epic to identify applicable patients accurately, pre- and post-SlicerDicer, there was an improvement from 4.95 out of 10 to 7.37 out of 10. Coordinators believed that if appropriate criteria are selected to narrow the search, then identifying applicable patients will be easier. Others believed that they will be able to identify most populations searched for, but if information is missing within a patient chart, that individual may be omitted from a search that is conducted. Based on opinions of the perception of time spent screening patients, pre- and post SlicerDicer, there was an improvement from 6.80 out of 10 to 3.93 out of 10, albeit with mixed reactions from individual coordinators. Now, additional time will be needed to properly identify needed populations due to inclusion and exclusion, and current procedural terminology (CPT) codes. Based on opinions of Epic as a whole, pre- and post SlicerDicer, there was a slight improvement from 6.83 out of 10 to 7.87 out of 10. Coordinators generally believed that Epic was a useful tool, and that it will continue to be enhanced in the future. There were noteworthy themes from the findings of these surveys. 
	A theme with ease of screening was accuracy, in that if International Classification of Disease (ICD) codes are used for more accurate diagnoses for specific study protocols, then stress from screening will be lessened. Amount and quality of information at admission, communication among patients and providers, variance in the electronic and written records, coder training and experience, and both unintentional and intentional errors, can contribute to inaccurate diagnosis for study protocols. These sources of error along the “patient trajectory” and along the “paper trail” can help evaluate situations where ICD codes can be used effectively for screening.25 A theme with accuracy of applicable patients for studies was missing information in patient charts. Oftentimes, patient information that satisfies eligibility criteria can be scattered in multiple information systems, databases, and patient documents. Automatic database queries that assemble pertinent clinical information for review by clinical research staff could be a solution for this issue.26 A theme regarding the hesitance that SlicerDicer will definitively decrease time spent screening is, again, CPT and ICD codes. Integrated data capture would be a way to ease the concerns of study coordinators who were surveyed. As stated previously, integrated data capture streamlines the data capture process by allowing a user to more easily fill out case report forms while reducing the risk of transcription error because data are entered directly into the electronic case report form. The electronic case report form data contain details about the capture of the information in the EHR. These values are synchronized with the EHR, and the details of changes are recorded, providing a complete, clear sequence of events, thus providing support for audits and monitoring visits.23 Automated data capture could decrease the amount of time coordinators spend looking up codes for the specific diagnoses of their patients. 
	There are several implications from the pre-/post-survey results.  As this project is site-specific to AHN, SlicerDicer could be a boon for the research operation of the network. Improved accuracy of identifying target populations will ultimately aid subject recruitment if coordinators are search the correct demographics. It would also be useful to see if adding criteria-specific classes to SlicerDicer would assist coordinators in saving time on screening. Many coordinators were apprehensive still about the time they will have to spend screening. Some coordinators believed that SlicerDicer could increase the amount of time spent on feasibility because of its ability to actually allow identification of a population with statistical merit. Additionally, time spent screening may be sacrificed for accuracy, so competing goals need to be addressed. One coordinator believed there would be no change in time spent screening because generating data on patient details was not time consuming prior to SlicerDicer. Again, significant improvements would be in accuracy of the report, not time saved to generate the report. AHN needs to align its goals appropriately because not all goals may be achievable using SlicerDicer. The perceptions of Epic as an EHR system were positive after exposure to SlicerDicer. Many coordinators thought that the system is very functional if they are allowed access to all capabilities. As well, coordinators believed that Epic has many beneficial tools that can help AHN become a more efficient hospital system.	
There has been a great amount of congruence between major findings of the pre-/post-intervention survey and expected results. It was a goal to have SlicerDicer improve opinions regarding the ease of screening, the ability to accurately identify patients for research studies, and the overall functionality of Epic, while improving opinions regarding the perception of time spent screening. However, there was one area with unexpected and ambiguous findings: the usefulness of Epic in generating adverse event reports. Many coordinators did not answer the question on both pre- and post-implementation surveys. Many coordinators were not familiar with the adverse event report or said that it was not covered in the SlicerDicer training session. Responses to the specific question were very limited on the pre- and post-intervention survey. Work needs to be done to familiarize coordinators with the capabilities of the adverse event report within Epic. There were limitations that affect the generalizability of the study findings for practice. A power analysis was conducted to determine the statistical significance of each of the five survey questions (Table 2). The findings from questions one and three were statistically significant with required sample sizes of five and eight, respectively. However, the findings from questions two, four, and five were not statistically significant with required sample sizes of fifty-six, twenty-nine, and 132. This is a pilot study, thus the effect size must be large. The results of my survey were also impacted by non-response bias. Coordinators chosen for the sample were unwilling or unable to participate in the survey. Non-response bias occurred because the responses that were received may have differed in meaningful ways from non-respondents. The study has low power and is more likely to provide a wide range of estimates of the magnitude of an effect. The definition of the variables of interest in the study could have been more clearly defined, but since this is a pilot study, all findings can be viewed as preliminary and can lead into future studies.
6.0 	DISCUSSION 
There are action steps that need to be taken to address the unexpected findings and major limitations of the study. As the ED visit report is a custom tool that is essential for tracking adverse events in study patients, it was surprising to see that many coordinators were unfamiliar with the tool. 
The major limitation of the pilot study was the lack of survey responses for both the pre-implementation and post-implementation surveys. However, because this is a very preliminary endeavor and that the survey and interventions are specific to AHN, this limitation can be a guide for future studies that the Research Institute undertakes.
It was positive to see that opinions regarding ease of screening, pre- and post-SlicerDicer, improved from 4.26 out of 10 to 7.57 out of 10. Because certain cohorts of patients can be selected, specific information can be found to identify potential exclusion criteria for patients being screened for studies. This may make the screening process for study coordinators much more efficient in the future.
Also encouraging was that opinions regarding the ability of Epic to identify applicable patients accurately, pre- and post-SlicerDicer, improved from 4.95 out of 10 to 7.37 out of 10. There is oftentimes an abundance of data within a patient chart, and SlicerDicer can hopefully start to subdivide pertinent data in more meaningful ways. SlicerDicer also allows for data to be collected based on specific patient populations. Instead of evidence-based practice, it is practice-based evidence. This tool will not only assist CRCs in identifying patients for suitable clinical trials, but will give providers with AHN more autonomy within Epic. An important development is that SlicerDicer, as a standalone database, is updated nightly with patient information from Epic so study coordinators will always have the most recent medical information to make informed decisions about patient recruitment. However, this is in the infant stages as deep dives into patient records are limited to physicians, quality, research, and administrative leadership. 
SlicerDicer will also reduce time spent screening patients which improved from 6.80 out of 10 to 3.93 out of 10. SlicerDicer, because of its many capabilities, can allow coordinators to conduct preliminary research within patient files to more efficiently determine whether patients are eligible for studies. This will not only increase accuracy of patient identification for studies but will allow patient recruitment to be more efficient.
With the advent of SlicerDicer as a component of Epic, the perception of Epic as a whole slightly improved from 6.83 out of 10 to 7.87 out of 10. Epic is a useful EHR tool, and the slightest of enhancements have created a more functional product. However, one practical issue regarding Epic is that it takes years to fully integrate the technology into a large health network such as AHN. Based on the further analysis of the study results, conclusions can be drawn and recommendations for AHN-specific action and opportunities for further research can be discussed. 

7.0 	Conclusions AND Recommendations 
Conclusions can be drawn from this study based on CRCs surveyed. One conclusion is that SlicerDicer was effective in significantly positively shifting the attitudes of AHN CRCs regarding ease of screening and identifying applicable patients for research studies. Another conclusion is that SlicerDicer solidified Epic’s standing as an effective EHR system. I am confident that Epic will continually be improved and that its capability and efficiency will only increase over time. A more lukewarm conclusion is that SlicerDicer will dramatically decrease the amount of time that AHN CRCs spend on screening. Though this cannot be adequately measured until coordinators are enabled the time to become deeply familiar with SlicerDicer, feasibility will be able to be measured. Though the results of this pilot study were promising, I have several recommendations for AHN and for opportunities of further research.
This pilot study, seeing as it was solely focused on CRCs employed by AHN, is very preliminary and will give AHN an opportunity in the future to more actively engage the foundation of its research operation. CRCs do much of the “grunt work” of research studies and their opinions are extremely valuable. One objective should be kept in mind: Accuracy should not be sacrificed for speed. With constant accrual of the most recent patient data made possible by SlicerDicer, the appropriate patients will be placed into appropriate studies. This information can be used as a tool for AHN research leadership as to how best attack the conundrum of electronic screening for clinical research. 
Opportunities for further research are numerous after the results of this study. A six-month or year-long follow-up study of SlicerDicer and its impact on physician/primary investigator efficiency would be very beneficial as it would truly gauge its effectiveness and compatibility with Epic. It would also give CRCs the opportunity for in-depth, hands-on practice with the technology. Data would be more readily available and similar surveys could be completed at the quarter, half-way, and final checkpoints of the follow-up study. AHN cannot assume that based on the sporadic responses of the coordinators surveyed for this pilot study that SlicerDicer is a panacea for their clinical research needs. Further follow-up efforts are needed to fully optimize electronic screening within the AHN Research Institute. 
8.0 	Public Health Implications
This issue is of public health significance because optimizing recruitment methods to clinical trials will ultimately forge new medical frontiers: new interventions to surgery, investigational pharmaceuticals, implantable and wearable devices, biospecimen collection, and diagnostic technologies. While increasing patient accruals to these therapeutic areas will have a direct and largely positive impact on the future delivery of health care, resources will remain scarce. That is the nature of the field. Physician investigators need to manage their time efficiently and public health trained staff will be at the forefront of developing and deploying new interventions like those detailed in this essay. 





AppEndix A: AHN IRB NO PURVIEW LETTER

APPENDIX B: BLANK PRE- AND POST-INTERVENTION SURVEYS
Masters Essay Study Coordinator Survey (Pre-Epic Modification)
Name:
Service Line/Department:
1.	On a scale of 1-10 (1 = not easy at all, 5 = fairly easy, 10 = very easy) how easy is screening based on diagnosis only using Epic?

2.	On a scale from 1-10 (1 = not accurate, 5 = fairly accurate, 10 = very accurate) how would you rate Epic’s ability to identify applicable patients?


3.	On a scale of 1-10 (1 = not much time, 5 = fair amount of time, 10 = long amount of time) what is your perception of the time you spend screening?

4.	On a scale of 1-10 (1 = not a useful system, 5 = fair system, 10 = excellent system) what is your perception of Epic as an EHR system as a whole?










Masters Essay Study Coordinator Survey (Post-Epic Implementation)
Name:
Service Line/Department:
1.	Following the group training and introduction to new EPIC search tools, on a scale of 1-10 (1 = not easy at all, 5 = fairly easy, 10 = very easy) how easy do you feel feasibility completion will be based on the search criteria available in SlicerDicer?

1.	 Following the group training and introduction to new EPIC search tools, on a scale from 1-10 (1 = not accurate, 5 = fairly accurate, 10 = very accurate) how would you rate Epic’s ability to identify eligible patient populations?

1.	Following the group training and introduction to new EPIC search tools, on a scale of 1-10 (1 = less time than prior to SlicerDicer implementation 5 = the same amount of time, 10 = more time) how much time do you feel you will spend completing feasibility?

1.	Following the group training and introduction to new EPIC tools, on a scale of 1-10 (1 = not a useful system, 5 = fair system, 10 = excellent system) what is your perception of Epic as an EHR system as a whole?





Appendix C: stata output from power analysis

Question 1: sampsi 4.26 7.57, sd1(1.96) sd2(1.40) power(0.8)
 
Estimated sample size for two-sample comparison of means
 
Test Ho: m1 = m2, where m1 is the mean in population 1
                    and m2 is the mean in population 2
Assumptions:
 
         alpha =   0.0500  (two-sided)
         power =   0.8000
            m1 =     4.26
            m2 =     7.57
           sd1 =     1.96
           sd2 =      1.4
         n2/n1 =    1.00
 
Estimated required sample sizes:
 
            n1 =        5
            n2 =        5
 
 
Question 2: sampsi 6.8 7.4, sd1(1.3) sd2(2) power(0.8)
 
Estimated sample size for two-sample comparison of means
 
Test Ho: m1 = m2, where m1 is the mean in population 1
                    and m2 is the mean in population 2
Assumptions:
 
         alpha =   0.0500  (two-sided)
         power =   0.8000
            m1 =      6.8
            m2 =      7.4
           sd1 =      1.3
           sd2 =        2
         n2/n1 =     1.00
 
Estimated required sample sizes:
 
           n1 =       56
            n2 =       56
 

Question 3: sampsi 6.83 3.93, sd1(1.34) sd2(2.41) power(0.8)
 
Estimated sample size for two-sample comparison of means
 
Test Ho: m1 = m2, where m1 is the mean in population 1
                    and m2 is the mean in population 2
Assumptions:
 
         alpha =   0.0500  (two-sided)
         power =   0.8000
            m1 =     6.83
            m2 =     3.93
           sd1 =     1.34
           sd2 =     2.41
         n2/n1 =    1.00
 
Estimated required sample sizes:
 
            n1 =        8
            n2 =        8
 

Question 4: sampsi 6.83 7.87, sd1(1.34) sd2(1.44) power(0.8)
 
Estimated sample size for two-sample comparison of means
 
Test Ho: m1 = m2, where m1 is the mean in population 1
                    and m2 is the mean in population 2
Assumptions:
 
         alpha =   0.0500  (two-sided)
         power =   0.8000
            m1 =     6.83
            m2 =     7.87
           sd1 =     1.34
           sd2 =     1.44
         n2/n1 =    1.00
 
Estimated required sample sizes:
 
            n1 =       29
            n2 =       29
 
 
Question 5: sampsi 4.5 5.44 , sd1(2.54) sd2(2.67) power(0.8)
 
Estimated sample size for two-sample comparison of means
 
Test Ho: m1 = m2, where m1 is the mean in population 1
                    and m2 is the mean in population 2
Assumptions:
 
         alpha =   0.0500  (two-sided)
         power =   0.8000
            m1 =      4.5
            m2 =     5.44
           sd1 =     2.54
           sd2 =     2.67
         n2/n1 =    1.00
 
Estimated required sample sizes:
 
            n1 =      121
            n2 =      121
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Ease of screening: 1 = not easy at all, 5 = fairly easy, 10 = very easy
Applicable patient ID accuracy: 1 = not accurate, 5 = fairly accurate, 10 = very accurate
Time spent screening patients: 1 = less time than prior to SlicerDicer implementation, 5 = same amount of time, 10 = more time
Perception of Epic as EHR system: 1 = not a useful system, 5 = fair system, 10 = excellent system




Ease of screening: 1 = not easy at all, 5 = fairly easy, 10 = very easy
Applicable patient ID accuracy: 1 = not accurate, 5 = fairly accurate, 10 = very accurate
Time spent screening patients: 1 = not much time, 5 = fair amount of time, 10 = long amount of time
Perception of Epic as EHR system: 1 = not a useful system, 5 = fair system, 10 = excellent system
Usefulness of Epic in generating AE reports: 1 = not useful, 5 = fairly useful, 10 = extremely useful 
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